Alpha Cognition won a European Patent Office grant covering a crystalline form of benzgalantamine, the active ingredient in ZUNVEYL, for mild-to-moderate Alzheimer’s disease.
Claims cover the solid form, related compositions, manufacturing methods, preparation processes, and medical-use protection.
Patent could extend protection for benzgalantamine into 2042, subject to standard requirements.
Grant can be validated across EPC states, supporting broader IP coverage in Europe.
ACOG•
